EXTENDED - TODAY ONLY: MarketBeat All Access For Just $399 $199 (save 50%)
×
S&P 500   3,953.94 (-0.25%)
DOW   33,808.40 (-0.12%)
QQQ   280.16 (-0.90%)
AAPL   140.58 (-2.52%)
MSFT   239.93 (-0.76%)
META   109.74 (+0.88%)
GOOGL   95.07 (-1.02%)
AMZN   92.23 (-1.83%)
TSLA   178.87 (-2.21%)
NVDA   156.31 (-1.24%)
NIO   10.53 (+4.05%)
BABA   79.93 (+5.34%)
AMD   73.59 (+0.55%)
T   18.93 (+0.58%)
MU   54.91 (-1.51%)
CGC   3.43 (+0.88%)
F   13.73 (+0.00%)
GE   85.40 (-0.08%)
DIS   94.10 (-1.66%)
AMC   7.42 (+1.23%)
PYPL   77.80 (-2.66%)
PFE   49.43 (-0.28%)
NFLX   279.00 (-0.77%)
S&P 500   3,953.94 (-0.25%)
DOW   33,808.40 (-0.12%)
QQQ   280.16 (-0.90%)
AAPL   140.58 (-2.52%)
MSFT   239.93 (-0.76%)
META   109.74 (+0.88%)
GOOGL   95.07 (-1.02%)
AMZN   92.23 (-1.83%)
TSLA   178.87 (-2.21%)
NVDA   156.31 (-1.24%)
NIO   10.53 (+4.05%)
BABA   79.93 (+5.34%)
AMD   73.59 (+0.55%)
T   18.93 (+0.58%)
MU   54.91 (-1.51%)
CGC   3.43 (+0.88%)
F   13.73 (+0.00%)
GE   85.40 (-0.08%)
DIS   94.10 (-1.66%)
AMC   7.42 (+1.23%)
PYPL   77.80 (-2.66%)
PFE   49.43 (-0.28%)
NFLX   279.00 (-0.77%)
S&P 500   3,953.94 (-0.25%)
DOW   33,808.40 (-0.12%)
QQQ   280.16 (-0.90%)
AAPL   140.58 (-2.52%)
MSFT   239.93 (-0.76%)
META   109.74 (+0.88%)
GOOGL   95.07 (-1.02%)
AMZN   92.23 (-1.83%)
TSLA   178.87 (-2.21%)
NVDA   156.31 (-1.24%)
NIO   10.53 (+4.05%)
BABA   79.93 (+5.34%)
AMD   73.59 (+0.55%)
T   18.93 (+0.58%)
MU   54.91 (-1.51%)
CGC   3.43 (+0.88%)
F   13.73 (+0.00%)
GE   85.40 (-0.08%)
DIS   94.10 (-1.66%)
AMC   7.42 (+1.23%)
PYPL   77.80 (-2.66%)
PFE   49.43 (-0.28%)
NFLX   279.00 (-0.77%)
S&P 500   3,953.94 (-0.25%)
DOW   33,808.40 (-0.12%)
QQQ   280.16 (-0.90%)
AAPL   140.58 (-2.52%)
MSFT   239.93 (-0.76%)
META   109.74 (+0.88%)
GOOGL   95.07 (-1.02%)
AMZN   92.23 (-1.83%)
TSLA   178.87 (-2.21%)
NVDA   156.31 (-1.24%)
NIO   10.53 (+4.05%)
BABA   79.93 (+5.34%)
AMD   73.59 (+0.55%)
T   18.93 (+0.58%)
MU   54.91 (-1.51%)
CGC   3.43 (+0.88%)
F   13.73 (+0.00%)
GE   85.40 (-0.08%)
DIS   94.10 (-1.66%)
AMC   7.42 (+1.23%)
PYPL   77.80 (-2.66%)
PFE   49.43 (-0.28%)
NFLX   279.00 (-0.77%)
NASDAQ:VBIV

VBI Vaccines - VBIV Stock Forecast, Price & News

$0.60
+0.00 (+0.48%)
(As of 11/29/2022 03:04 PM ET)
Add
Compare
Today's Range
$0.60
$0.63
50-Day Range
$0.58
$0.78
52-Week Range
$0.55
$3.42
Volume
10,303 shs
Average Volume
725,289 shs
Market Capitalization
$155.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

VBI Vaccines MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
539.0% Upside
$4.00 Price Target
Short Interest
Bearish
5.63% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
0.53mentions of VBI Vaccines in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.36) to ($0.27) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.81 out of 5 stars

Medical Sector

855th out of 1,038 stocks

Pharmaceutical Preparations Industry

418th out of 510 stocks

VBIV stock logo

About VBI Vaccines (NASDAQ:VBIV) Stock

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.

Receive VBIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VBI Vaccines and its competitors with MarketBeat's FREE daily newsletter.

VBIV Stock News Headlines

VBI Vaccines Inc
See More Headlines
Receive VBIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VBI Vaccines and its competitors with MarketBeat's FREE daily newsletter.

VBIV Company Calendar

Last Earnings
11/08/2021
Today
11/29/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/06/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VBIV
Fax
N/A
Employees
149
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+564.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-69,750,000.00
Net Margins
-12,752.30%
Pretax Margin
-12,752.30%

Debt

Sales & Book Value

Annual Sales
$630,000.00
Book Value
$0.56 per share

Miscellaneous

Free Float
233,723,000
Market Cap
$155.50 million
Optionable
Optionable
Beta
1.83

Key Executives

  • Mr. Jeffery R. Baxter F.C.M.A. (Age 61)
    FCMA, Pres, CEO & Director
    Comp: $1.04M
  • Mr. Christopher McNulty (Age 45)
    CFO, Head of Bus. Devel. & Director
  • Dr. David Evander Anderson (Age 52)
    Chief Scientific Officer
    Comp: $605.07k
  • Dr. Francisco Diaz-Mitoma FRCPC (Age 67)
    M.D., Ph.D., Chief Medical Officer
    Comp: $652.09k
  • Nicole Anderson
    Director of Corp. Communications & Investor Relations
  • Ms. Athena Kartsaklis (Age 57)
    Sr. VP of Fin., Chief Compliance Officer & Principal Financial Officer
  • Ms. Nell BeattieMs. Nell Beattie (Age 34)
    Chief Bus. Officer
  • Mr. Avi Mazaltov (Age 60)
    Global Head of Manufacturing & GM of SciVac
  • Mr. Misha Nossov
    Sr. VP of Market Access & Commercial
  • Mr. T. Adam Buckley (Age 46)
    Sr. VP of Bus. Devel.













VBIV Stock - Frequently Asked Questions

Should I buy or sell VBI Vaccines stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for VBI Vaccines in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VBIV shares.
View VBIV analyst ratings
or view top-rated stocks.

What is VBI Vaccines' stock price forecast for 2023?

2 Wall Street analysts have issued 12 month price objectives for VBI Vaccines' shares. Their VBIV share price forecasts range from $2.00 to $6.00. On average, they predict the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 567.6% from the stock's current price.
View analysts price targets for VBIV
or view top-rated stocks among Wall Street analysts.

How have VBIV shares performed in 2022?

VBI Vaccines' stock was trading at $2.34 at the start of the year. Since then, VBIV stock has decreased by 74.4% and is now trading at $0.5992.
View the best growth stocks for 2022 here
.

When is VBI Vaccines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 6th 2023.
View our VBIV earnings forecast
.

How were VBI Vaccines' earnings last quarter?

VBI Vaccines Inc. (NASDAQ:VBIV) released its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.01. The biopharmaceutical company had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.26 million. VBI Vaccines had a negative net margin of 12,752.30% and a negative trailing twelve-month return on equity of 93.54%.

What other stocks do shareholders of VBI Vaccines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VBI Vaccines investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird (), Wellington Shields () and Macquarie ().

What is VBI Vaccines' stock symbol?

VBI Vaccines trades on the NASDAQ under the ticker symbol "VBIV."

Who are VBI Vaccines' major shareholders?

VBI Vaccines' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.21%), State Street Corp (1.79%), Cambridge Investment Research Advisors Inc. (1.21%), Vanguard Group Inc. (1.02%), Renaissance Technologies LLC (0.35%) and Bank of New York Mellon Corp (0.28%). Insiders that own company stock include Life Sciences Maste Perceptive, Nell Beattie and Perceptive Advisors Llc.
View institutional ownership trends
.

How do I buy shares of VBI Vaccines?

Shares of VBIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VBI Vaccines' stock price today?

One share of VBIV stock can currently be purchased for approximately $0.60.

How much money does VBI Vaccines make?

VBI Vaccines (NASDAQ:VBIV) has a market capitalization of $154.75 million and generates $630,000.00 in revenue each year. The biopharmaceutical company earns $-69,750,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis.

How many employees does VBI Vaccines have?

The company employs 149 workers across the globe.

How can I contact VBI Vaccines?

VBI Vaccines' mailing address is 222 Third Street Suite 2241, Cambridge MA, 02142. The official website for the company is www.vbivaccines.com. The biopharmaceutical company can be reached via phone at (617) 830-3031 or via email at ir@vbivaccines.com.

This page (NASDAQ:VBIV) was last updated on 11/29/2022 by MarketBeat.com Staff